All In Biotech

Drug Trial Radar · NCT07906145

A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of QLS2416 Injection in Participants With Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jun 2029

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of QLS2416 injection in participants with autoimmune diseases (AID). The main questions it aims to answer are: • What is the safety and tolerability profile of single and multiple ascending doses of QLS2416 injection? This study consists of two parts. Participants will receive QLS2416 injection via subcutaneous administration in dose-escalation part and dose-expansion part. Safety assessments will be conducted throughout the study. Efficacy assessments will vary by disease indication.

Conditions

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis (RA)
  • Primary Sjögren's Syndrome (pSS)
  • Systemic Sclerosis (SSc)

Interventions

  • QLS2416 InjectionDrug

    QLS2416 is a novel biologic agent administered via subcutaneous injection. Dose levels range from 0.025 mg to 6.0 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of QLS2416 InjectionTime frame: Up to 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.